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Bilaterality of breast cancer is an indicator of constitutional cancer susceptibility; however, the molecular
causes underlying this predisposition in the majority of cases is not known. We hypothesize that epigenetic
misregulation of cancer-related genes could partially account for this predisposition. We have performed
methylation microarray analysis of peripheral blood DNA from 14 women with bilateral breast cancer com-
pared with 14 unaffected matched controls throughout 17 candidate breast cancer susceptibility genes
including BRCA1, BRCA2, CHEK2, ATM, ESR1, SFN, CDKN2A, TP53, GSTP1, CDH1, CDH13, HIC1, PGR,
SFRP1, MLH1, RARB and HSD17B4. We show that the majority of methylation variability is associated with
intragenic repetitive elements. Detailed validation of the tiled region around ATM was performed by bisulphite
modification and pyrosequencing of the same samples and in a second set of peripheral blood DNA from 190
bilateral breast cancer patients compared with 190 controls. We show significant hypermethylation of one
intragenic repetitive element in breast cancer cases compared with controls (P 5 0.0017), with the highest
quartile of methylation associated with a 3-fold increased risk of breast cancer (OR 3.20, 95% CI 1.78–5.86,
P 5 0.000083). Increased methylation of this locus is associated with lower steady-state ATM mRNA level
and correlates with age of cancer patients but not controls, suggesting a combined age–phenotype-related
association. This research demonstrates the potential for gene-body epigenetic misregulation of ATM and
other cancer-related genes in peripheral blood DNA that may be useful as a novel marker to estimate
breast cancer risk.
Accession numbers: The microarray data and associated .BED and .WIG files can be accessed through Gene
Expression Omnibus accession number: GSE14603.
INTRODUCTION
Breast cancer is one of the most common cancers in the
Western world affecting one in 10 women during their lifetime
(1). Mutations in the breast cancer susceptibility genes,
BRCA1 and BRCA2, and, to a lesser extent, CHEK2, TP53
and ATM, account for 25% of familial breast tumours (2).
The remaining 75% of familial breast cancers (BRCAx
tumours) and the majority of sporadic tumours are not attribu-
table to known mutations in any of these genes. In bilateral
cases of breast cancer (a second primary tumour in the
contra-lateral breast), it is believed that the underlying
‘mutation’ is not limited to the epithelial cells of one breast,
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but rather is systemic (3). The importance of epigenetic
changes in cancer development is now well established;
however, the role of epigenetic changes as a mechanism for
increased cancer risk is yet to be fully explored. Therefore,
we hypothesized that some of the systemic epigenetic
changes are either inherited or acquired in the early develop-
mental stages and therefore should be detectable in the
tissues other than breast, such as peripheral blood DNA
(4,5). Since carcinogenesis induces numerous genetic and epi-
genetic changes, the study of tumour cells alone cannot dis-
tinguish whether epigenetic inactivation of tumour
suppressor genes is a cause or a consequence of the neoplastic
process in breast cancer (6). Identification of epimutations in
the tissues and cells that are not affected by the disease
process would favour causal association. Therefore, we
aimed to identify epigenetic misregulation of candidate
genes in the normal peripheral blood cells of cancer patients
compared with controls.
Epigenetics is the investigation of ‘any information that is
carried by the genome that is not coded by DNA’ and includes
DNA methylation, histone modifications, chromatin structure
and non-coding RNA-mediated regulation of gene expression
and various other genomic functions (7). DNA methylation
studies in cancer revealed two main types of changes: hyper-
methylation of promoter CpG islands and hypomethylation
of repetitive DNA sequences (8). DNA methylation is
heritable through mitosis and is copied to the new strand
by DNA methylatransferase 1 during DNA replication.
Meiotic heritability of DNA methylation states, particularly
transposon-associated methylation, has been shown in
mice and in plants; however, it is not yet clear whether
DNA methylation is heritable through meiosis in humans
(9,10). Recent evidence suggests that epimutations are likely
to arise somatically (11). Apart from trans-generational
inheritance of epigenetic states, single-generation germline
epigenetic effects are also possible. During germ cell develop-
ment, the epigenome is reprogrammed with two waves of
demethylation and re-establishment of DNA methylation
marks allowing the possibility of errors that could persist in
the germline (12). We have previously shown that the male
germline exhibits locus-, cell- and age-dependent DNA
methylation differences and that DNA methylation variation
is significant across unrelated individuals, at a level that, by
far, exceeds DNA sequence variation (13). This has allowed
us to hypothesize that epigenetic variation in normal somatic
cells, which need not be transgenerational, could be a predis-
posing factor for cancer.
DNA methylation alterations have been studied extensively
in breast tumour tissues most recently with genome wide ana-
lyses revealing hypermethylated as well as hypomethylated
loci compared with matched adjacent tissues (14). Approxi-
mately 100 candidate genes have been reported throughout
the literature as promoters hypermethylated at varying fre-
quencies in breast cancers (Pubmeth http://matrix.ugent.be/
pubmeth/search.html). For our study, we have selected genes
that have either previously been identified as breast cancer sus-
ceptibility genes with known mutations in familial cases
(BRCA1, BRCA2, ATM, CHEK2, TP53) or genes that are fre-
quently hypermethylated in sporadic breast cancers (ESR1,
SFN, CDKN2A, GSTP1, CDH1, CDH13, HIC1, PGR,
SFRP1, MLH1, RARB and HSD17B4). We have used a two-
stage design to firstly identify methylation variable positions
(MVPs) in peripheral blood DNA and then secondly to test
selected sites for an association with breast cancer in a
larger sample set.
RESULTS
Microarray analysis
We performed differential DNA methylation analysis using a
methylation-sensitive enzyme-based approach to compare
the methylation status of peripheral blood DNA of 14 bilateral
breast cancer cases with 14 matched controls. We have
designed a custom-tiled microarray covering a total of 4 Mb
to completely cover 17 breast cancer susceptibility genes
(Supplementary Material, Fig. S1A) and an additional 34
genes also captured in the flanking regions (Supplementary
Material, Table S1). Using the Model-based Analysis of
2-Color Arrays (MA2C) algorithm, we were able to detect
181 significantly variable regions (P , 0.001) across the 28
individuals, which we have termed inter-individual MVPs.
These included 143 intragenic, or gene-body, MVPs and 38
intergenic regions not associated with known gene promoters
(Supplementary Material, Table S2). We observed intragenic
methylation variability in each of the remaining targeted
genes ATM, PGR, CDH1, CDH13, CHEK2, MLH1, RARB,
HSD17B4, ESR1, SFRP1 and CDKN2A. Of all of the genes
tested, we detected no significant intragenic methylation varia-
bility in six of the targeted genes including BRCA1, BRCA2,
TP53, SFN, HIC1 and GSTP1 (Supplementary Material,
Fig. S2).
Methylation variability is located in intragenic
repetitive elements
Although the repetitive sequences themselves are not tiled, the
enrichment of unmethylated genome can assess methylation
status of the repetitive sequences by probing the unique
sequences flanking the repeats (gaps in the tiling microarrays)
(Supplementary Material, Fig. S1B). To confirm the associ-
ation of MVPs with repetitive elements, we have calculated
the distance from the middle of each peak to the nearest repeti-
tive element for each of the 181 identified loci. This analysis
identified 80/181 (44%) of MVPs within 100 bp of the
nearest repetitive element and 60% within 200 bp. This distri-
bution is significantly closer to repetitive elements than can be
expected by random chance (P ¼ 7.39e–07, Kolmogorov–
Smirnov test) (Fig. 1A). The distribution of repeat element
type is not significantly different to the distribution throughout
the genome. By aligning each gene at the transcription start
sites (TSSs) and averaging the MATScores, we were able to
generate a general picture of methylation variability over the
first 10 kb of genes longer than 10 kb or across the first 5 kb
of shorter genes. This reveals very low methylation variability
over all gene promoters up to the TSS and a sharp increase in
variability over the first 1 kb of intragenic sequence followed
by periodic increase and decrease in variability every 2 kb
(Fig. 1B).
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Investigation of DNA methylation of ATM
We have performed a detailed validation of the MVPs within
the targeted region surrounding one gene, ATM, which we
have selected because it is known to contain germline
mutations in familial breast cancer cases with a clear patho-
genic role and it contains several intragenic MVPs associated
with repetitive elements (Fig. 2A). We used bisulphite modi-
fication coupled with pyrosequencing assays to map methyl-
ated cytosines in the repetitive elements nearest to six MVPs
in the targeted region surrounding ATM. We first analysed
the 14 matched case–control paired samples that we per-
formed the microarray analysis on. Pair-wise comparison
of methylation percentages confirmed the significant
inter-individual variability in each of the loci identified by
the microarray as exemplified by ATMmvp2a with 8/14
pairs significantly different (P , 0.05, Wilcoxon signed rank
sum test) (Fig. 2B). Combined data from all of the 14 cases
and controls revealed no statistically significant differences
overall between patients and controls; however, the highest
range of methylation across individuals were observed in the
intragenic regions nearest the TSSs. The two most variable
loci, ATMmvp1 and ATMmvp2, are both 4 kb downstream
of the start sites of the genes NPAT and ATM, respectively
(Fig. 2C). We detected no significant difference in genome-
wide methylation as assessed by the pyrosequencing assay
for LINE1; therefore, any differences detected are unlikely
to be due to overall genome-wide methylation differences.
Furthermore, in each of the 14 cases and controls, we detected
no methylation of the ATM promoter CpG island in the peri-
pheral blood DNA.
We performed a second stage of validation for the most
variable loci, MVP2, within the ATM gene as well as the
ATM CpG island and LINE1 assays in peripheral blood
DNA from 190 bilateral breast cancer patients compared
with 190 controls (Fig. 3). Again, we detected no significant
difference between cases and controls in the LINE1 assay or
the ATM CpG island. The LINE1 assay did, however, show
inter-individual variability with genome-wide methylation
values ranging from the lowest individual at 48% to the
highest at 74% (median 56%). We did detect a significant
increase in methylation of ATMmvp2b in the bilateral breast
cancer patients (range 72.8–98.4%, mean 91.4%) compared
with control individuals (range 53–98%, mean 89.8%) (P ¼
0.001686, Wilcoxon rank sum test) (Supplementary Material,
Fig. S3). We have used an inter-quartile analysis of the ATM
mvp2b methylation data to reveal a significant increase in
methylation in cases in the highest quartile (P ¼ 0.0011
using x2 test), which is associated with a 3-fold increased
risk of breast cancer (odds ratio—OR 3.20, 95% CI 1.78–
5.86, P ¼ 0.000083), compared with the lowest quartile
(Table 1). We have analysed these data to identify whether
the methylation status of this locus is associated with any phe-
notypic characteristics. We have investigated the age at blood
draw (median 6.6 years after second diagnosis), age at first and
second diagnoses and the time between diagnoses (Table 2).
There was no association between the methylation level and
tumour morphology, age at first full-term pregnancy, age at
menarche, menopausal status, body mass index, weight,
parity and the number of affected first-degree relatives (data
not shown). Only the age and the age of diagnoses in the
breast cancer patients were significantly associated with the
methylation status (adjusted for multiple testing, P ¼
0.01035). Interestingly, even though the controls were age-
matched with patients, age was not correlated with the methyl-
ation status in the controls (r ¼ 20.1077, P ¼ 0.07), only in
the cases at blood draw (r ¼ 0.242, P ¼ 0.0004), at first diag-
nosis (r ¼ 0.189, P ¼ 0.0045) and at second diagnosis (r ¼
0.251, P ¼ 0.0002) (Supplementary Material, Fig. S4).
It is well defined that different tissues show differential
methylation particularly between different peripheral blood
cell types (CD4þ and CD8þ T cells compared with B
cells) (15). Therefore, the small effect (increase in methylation
at ATM mvp2b) in patients compared with controls could be
Figure 1. Methylation microarray analysis of 17 genes reveals methylation
variability in repetitive elements. (A) The distance from each of the MVP to
the nearest repetitive element was calculated for each of the 181 distinct
MVPs revealing 44% of peaks within 100 bp of the nearest repetitive
element. Random placement of 181 simulated MVP peaks reveals a distri-
bution containing only 26% of peaks within 100 bp of the nearest repetitive
element. Kolmogorov–Smirnov test was used to determine the significance
of the difference in distribution. (B) The smoothed average of MATScores
(+2 SD in red) for genes aligned at the TSS reveals periodic increase in
methylation variability across the first 10 kb (of genes .10 kb) or across
the first 5 kb (of shorter genes, median 4.5 kb).
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Figure 2. Investigation of ATM gene methylation. (A) Methylation microarray data for the ATM gene locus. Seven methylation variable peaks were detected
across the tiled region surrounding the ATM gene. Data are presented as a custom WIG file track on the UCSC genome browser. (B) Pair-wise comparison of
ATM mvp2a methylation reveals increased methylation in 5/14 bilateral breast cancer patients (blue) compared with matched controls (yellow). Methylation of
six CpG dinucleotides within the repetitive element mvp2a was determined by pyrosequencing. Pair-wise Wilcoxon signed rank sum test was used to determine
statistical significance (# indicates P , 0.05). (C) DNA methylation analysis of MVPs reveals significant variability detected within the ATM gene. LINE 1 assay
shows no significant differences in methylation of LINE1 repetitive elements in peripheral blood DNA of cases (blue) compared with controls (yellow). Methyl-
ation variability was detected in mvp1b, mvp2a, mvp2b, mvp3 and mvp4. Box and whisker plots represent median (centre line), inter-quartile range (box) and
95th percentiles (whisker), and samples outwith this range are represented as points.
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Figure 3. Methylation of LINE1, ATM CpG island, mvp2a and mvp2b in 190 bilateral breast cancer cases compared with 190 controls. (A) Schematic of the
genomic location of the ATM CpG island (CGI) at the TSS and at mvp2a and mvp2b within the second intron of ATM. (B) Pyrosequencing-based methylation
analysis of 190 bilateral breast cancer cases compared with 190 matched controls reveals no methylation in the promoter CpG island and significant inter-
individual methylation variability in the intronic mvp2a and mvp2b. Significant hypermethylation of mvp2b is detected in bilateral breast cancer cases com-
pared with controls (P ¼ 0.0017, Wilcoxon signed rank sum test). Box and whisker plots represent median (centre line), inter-quartile range (box) and 95th
percentiles (whisker), and samples outwith this range are represented as points. (C) Kernel density plot of methylation values in cases (solid line) compared
with controls (dotted lines) showing overlapping distributions for LINE1, ATM CpG island and ATM mvp2a and a skewed distribution of methylation at ATM
mvp2b in the cases.
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due to a larger effect in a small subpopulation of cells within
the heterogeneous peripheral blood cell population. We have
addressed this question by isolation of B cells, T cells and
monocytes from peripheral blood mononuclear cells
(PBMCs) from two healthy controls and investigating the
methylation status of this locus. We show that the methylation
of ATMmvp2b does not show cell-specific methylation differ-
ences between these three blood cell fractions, and all frac-
tions have similar methylation levels to the whole PBMCs
(Supplementary Material, Fig. S5).
In order to investigate the relationship between methylation
at ATM mvp2b and expression of ATM, we screened a large
panel of cancer cell lines and observed a similar methylation
range as seen in peripheral blood (77–99%); however, the dis-
tribution of methylation percentages is significantly higher in
the cancer cell lines than in the peripheral blood DNA of
the patients and controls (P , 1e–14, Wilcoxon signed rank
test) (Fig. 4A). We performed quantitative RT–PCR for
ATM expression in five breast cancer cell lines (MCF7,
T47D, SKBR3, MDA-MB-231 and BT549) and analysed pre-
existing gene expression data for 18 mesenchymal tumour cell
lines (16) (Fig. 4B and C). In both cases, we observed a cor-
relation between the methylation of the intragenic repetitive
element and expression of ATM (Spearmans rho 20.9 and
20.33, respectively).
DISCUSSION
This project is the first comprehensive DNA methylation study
using high-density tiling arrays to look for methylation vari-
ation in white blood cells of bilateral breast cancer patients
compared with controls. It is well established that identifi-
cation of high-risk patients guiding the use of preventative
treatment such as intensive surveillance (e.g. mammography),
chemoprevention (e.g. tamoxifen) or prophylactic surgery
(e.g. radical mastectomy) can significantly reduce the burden
of breast cancer (17). Therefore, all additional tools with
which we can predict a patient’s risk of cancer, such as
DNA methylation markers, would improve our ability to
identify those at high risk. The difficulty in finding genetic
markers of common breast cancer risk has been recently exem-
plified by a number of extraordinarily large case–control
studies that have identified only minor increases in breast
cancer risk (18,19). The overall goal of this current study
was to screen candidate genes for epigenetic differences in
peripheral blood DNA to identify markers of common breast
cancer risk. We believe that DNA methylation markers
could be more informative, as they are more stable than
other candidate biomarkers such as RNA or protein-based
markers, and can act as a surrogate for environmental
exposures (20). The extent to which epigenetic markers can
be used for risk assessment is yet to be fully explored.
‘Gene body methylation’ is a recent term describing the
DNA methylation that occurs throughout the gene from the
TSS, through exons and introns, to the 30 untranslated region
(21–23). In Arabidopsis, the level of gene-body methylation
has been linked to the level of gene transcription such that
gene-body methylation was absent in genes that were not tran-
scribed, was low in genes that were transcribed at low levels,
higher levels of methylation in the highest transcribed genes
but even higher methylation levels in genes that had inter-
mediate levels of transcription (22). Gene-body methylation
is also more associated with genes on the active X chromo-
some rather than on the inactive X-chromosome (21). The
association with the transcription of individual genes and
gene-body methylation has not yet been investigated in
cancer. We have recently suggested that gene-body methyl-
ation in the human genome may be associated with intragenic
repetitive elements and that altered methylation in the gene-
Table 1. Inter-quartile analysis of ATM mvp2b methylation reveals increased risk of breast cancer in the highest quartile
ATM mvp2b Control (n ¼ 189) Case (n ¼ 190) x2 OR 95% CI P-value P-trend
Q4 91.5–98.4% 32 63 3.20 1.78–5.86 0.000083 0.00032
Q3 88.6–91.5% 48 44 1.44 0.81–2.58 0.215
Q2 88.6–91.5% 50 47 1.60 0.90–2.87 0.108
Q1 53.0–88.6% 59 36 0.0011 1
Table 2. Association between methylation of ATM mvp2b and phenotypic data from the bilateral breast cancer patients and controls reveals an association
between methylation and age in cases but not in controls
Cases, median
(range)
Cases, P-valuea Cases,
P-adjustedb
Controls, median
(range)
Controls,
P-valuea
Controls,
P-adjustedb
Age at blood draw 62.8 (37.5–79.6) 0.00109 0.01035 62.8 (37.1–79.4) 0.106 0.4028
Age at first diagnosis 47 (26–64) 0.0145 0.0918 NA NA NA
Age at second diagnosis 56 (26–70) 0.000487 0.0093 NA NA NA
Time between
diagnoses
6 years (0–26) 0.177 0.4204 NA NA NA
NA, not applicable.
aLinear model regression.
bFDR corrected for multiple testing.
Signifies significant association (P, 0.05).
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body may be a mechanism of modulating the level of tran-
scription (24). In the present study, we show for the first
time that the methylation of one intragenic repetitive
element inversely correlates with the expression of the gene
which supports this hypothesis. Although there are numerous
examples in the literature showing that active genes have
more gene-body methylation levels than inactive genes, all
of these studies compare the gene body methylation levels
of one gene with another and compare the expression levels
(22). These studies make a distinction between ‘On’
expression and gene-body methylation compared with ‘Off’
expression and no gene-body methylation. We suggest from
our data that the level of gene-body methylation may be mod-
ulating or fine-tuning the level of expression of the active
genes. To date, there has been no report looking at the
subtle differences in gene-body methylation across samples
and associating that with the expression of the same gene in
those samples. Therefore, our study is the first report of an
association between different levels of gene-body methylation
and expression of the same gene.
How gene-body methylation may alter the gene expression,
or alternatively how expression level may affect the
methylation level, is still not clear. The mvp within ATM
that we have identified could be a reporter of a more extended
regulatory epigenetic profile at ATM, similar to a tag SNP for a
region of linkage disequilibrium in DNA sequence variation.
Alternatively, this region could be involved in the regulation
of unannotated non-coding transcript(s) or antisense tran-
scripts that regulate the sense gene (22). Recent reports have
shown a high level of antisense transcription throughout the
genome which could be involved in gene regulation, which
suggests new levels of understanding of the process of tran-
scriptional regulation (25,26).
Our study of the breast cancer susceptibility genes has pro-
vided evidence that the regions of inter-individual methylation
variability are located within repetitive elements, particularly
SINEs (Alu sequences), and that the variability is highest at
1 kb downstream of the TSSs and increases periodically
along the gene. We interpret this increased variability as the
point in the genome where the methylation along the chroma-
tin is changing from unmethylated at the promoters to fully
methylated in the gene-body. We have identified one repetitive
element, ATM mvp2b, which is significantly more methylated
in the peripheral blood DNA of women affected with bilateral
breast cancer compared with matched control individuals. On
its own, this is not sufficient to be considered a potential diag-
nostic test, as there is considerable overlap between cases and
controls and the receiver operating curve area under the curve
Figure 4. Correlation between methylation of ATM mvp2b and expression of ATM in cancer cell lines. (A) Methylation analysis in 62 cancer cell lines reveals a
similar range of methylation as in PBMCs of breast cancer patients (77–99%); however, the distribution is skewed towards increased methylation in the cancer
cell lines (green). Methylation distributions of breast cancer patients (red) and controls (black) are shown for comparison. (B) ATM expression was determined
by qRT–PCR in the five breast cancer cell lines and by gene expression microarray data (C) for a panel of sarcoma cell lines. Error bars represent SEM from
triplicate qRT–PCR experiments. Correlation between methylation and expression is shown using Spearmans rank correlation coefficient.
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of 0.59 supports this lack of specificity as a diagnostic.
However, this may improve in combination with similar
markers from the other genes that we have identified, if such
markers provide an additive effect. Interestingly, not all
genes showed signs of inter-individual methylation variability.
For some of the genes, this could be explained by the short
length (e.g. SFN, GSTP1 and HIC1); however, this is not the
case for other longer genes which could represent genes
with conserved methylation patterns (e.g. BRCA1, BRCA2
and TP53) compared with other long genes that show high
levels of methylation variability (e.g. CDH13).
The ataxia telangiectasia (A-T) mutated (ATM) gene is
considered a breast cancer susceptibility gene, as female
heterozygotes from A-T families have an increased risk of
breast cancer and a number of breast cancer families have
been identified with germline ATM mutations (27,28).
Although one small study by Vo et al. identified increased
ATM promoter methylation associated with decreased
expression in locally advanced sporadic breast cancers,
numerous other reports suggest no evidence of promoter
methylation of this gene in breast cancers (29–32). One
finding that is consistent is that ATM expression is often
reduced in breast tumours (31–34). This could be explained
by genetic haploinsufficiency (35); however, our data in
peripheral blood DNA and cancer cell lines suggest a novel
mechanism of decreased expression mediated by aberrant gene-
body methylation, which warrants further investigation in
tumour tissues. We propose that if normal tissues of the individ-
ual, including mammary epithelial cells, express lower levels of
ATM owing to aberrantly increased gene-body methylation, then
these individuals may be more susceptible to DNA mutations in
those cells.
The biggest risk factor for breast cancer and indeed most
cancers is increasing age. The incidence of breast cancer in
women doubles for every 10 years until menopause with a
relative risk of .10-fold (36). An association between DNA
methylation and increasing age has also been reported, for
example increased DNA methylation variability in older
twins compared with younger twins and increasing variability
with increasing age in familial clusters (37,38). However, we
have found that the association between the level of methyl-
ation at ATM mvp2b and increasing age is only associated
in the bilateral breast cancer patients and not in controls.
This suggests that the relationship between age and DNA
methylation may be more dependent on the phenotype of the
individuals, in this case cancer, and may be due to other pre-
disposing environmental exposures that accumulate with age.
One of the confounding factors which we cannot rule out in
this study is the long-term effects of previous therapy in the
patients that are not present in the controls. Future studies
will need to investigate peripheral blood samples taken
before the initiation of treatment preferably in prospectively
collected cohort studies to rule out this possibility. However,
if therapy accounted for an overall difference in genome-wide
DNA methylation, the LINE1 assay for genome-wide methyl-
ation and the other unique sites tested (ATM mvp2a) would
have detected this, which it did not. Another confounding
factor is the effect of tissue-specific methylation. Although
we have shown that in two healthy controls there is no evi-
dence for cell-type-specific methylation of this locus, we
cannot rule out this possibility in cancer patients. Therefore,
this needs to be addressed in cancer patients.
In summary, we have shown that inter-individual variability
in gene-body methylation is associated with repetitive elements
and that it is possible to identify regions of significant differ-
ences between bilateral breast cancer patients and controls
that may be useful as additional surrogate markers for breast
cancer risk. This research also demonstrates the correlation
between the level of gene-body methylation and mRNA level
of a single gene and highlights the potential for gene-body epi-
genetic regulation of gene transcription. Finally, this work also
supports the need to interrogate whole epigenomes, including
repetitive elements, using tiling arrays or unbiased next-
generation sequencing approaches to investigate the full comp-
lement of methylation variability across the genome.
MATERIALS AND METHODS
Clinical sample
For the microarray analysis, peripheral blood DNA samples
from 14 women with bilateral breast cancer were compared
with the DNA samples from 14 age- and ethnicity-matched
controls. The cases were selected by being (i) BRCA1 and
BRCA2 mutation negative, confirmed clinically; (ii) metachro-
nous tumours (separate sites) (iii) and those meet the bilateral
case criteria set by Chaudary et al. (39), namely (a) subsequent
tumour contains in situ component; (b) distinct histological
types; (c) subsequent tumour has greater degree of differen-
tiation; (d) no evidence of metastatic spread from ipsilateral
tumour. These samples were collected with ethics approval
from the Institute for Womens Health, Toronto, Canada. Per-
ipheral blood DNA samples from a second set of 190 bilateral
cases and 190 controls were obtained from the British Breast
Cancer study (40,41). Bilateral breast cancer patients were
ascertained through the English and Scottish cancer registries,
controls were friends or non-blood relatives of breast cancer
patients. Controls were age-matched to patients at the age at
blood draw (within +2 months) and all patients and controls
were Caucasians resident in the UK. Written informed consent
was obtained from all participants, and the study was approved
by the South East Multicentre Research Ethics Committee.
DNA methylation profiling using microarrays
A custom oligonucleotide tiling array was designed to target
the testable genomic regions (plus 100 kb flanking sequence)
of genes, including breast cancer susceptibility genes BRCA1
(82 kb), BRCA2 (86 kb), CHEK2 (57 kb) and ATM (143 kb)
along with other genes that are known to be commonly
methylated in breast cancer, including ESR1 (296 kb), SFN
(1.3 kb), CDKN2A (27 kb), TP53 (19 kb), GSTP1 (2.8 kb),
CDH1 (96 kb), CDH13 (1169 kb), HIC1 (4.0 kb), PGR
(92 kb), SFRP1 (47 kb), MLH1 (57 kb), RARB (97 kb),
HSD17B4 (90 kb). Arrays were designed by and performed
by Nimblegen Inc. Specified regions were from UCSC
HG17 with overlapping 50mer probes every 21 bp excluding
repeat masked regions, and the probe set was replicated four
times on the chip and averaged data were used for analysis.
In addition to the 17 targeted genes, we also captured 26
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genes and 12 partial genes which were peripherally targeted in
the flanking regions by these tiling arrays (Supplementary
Material, Table S1).
The general principle of these DNA methylation arrays con-
sists of hybridization of the unmethylated fraction of genomic
DNA to the microarray containing oligonucleotides that rep-
resent the genomic region of interest. We performed the
enrichment as described previously (42). Briefly, we used a
cocktail of three methylation-sensitive enzymes (HpaII, AciI
and Hin6I) to digest individuals genomic DNA and used
ligation-mediated PCR to amplify products which were
cleaned using Qiagen PCR cleanup kit (Qiagen, Canada),
labelled with either Cy3 or Cy5 dyes and co-hybridized in
matched pairs to the custom array. Hybridization intensity cor-
relates with the DNA methylation status at the genomic locus
homologous to each oligonucleotide on the array. MA2C was
used for normalization, peak detection (using a cut-off of P ,
0.001) and generation of MATScores for each probe (43).
Pyrosequencing
DNA samples were bisulphite-converted using EZ-96 DNA
Methylation-Gold kit (Zymo Research, Orange, CA, USA)
following the manufacturers protocol. Pyrosequencing of
LINE1 elements was performed using the LINE1 assay
(Biotage, Hertford, UK). All other pyrosequencing assays
were designed using the PyroQ assay design software
(primers in Supplementary Material, Table S3). All pyrose-
quencing assays for repetitive elements included at least one
primer in a unique sequence outside of the repeat and followed
by a unique nested primer pair for some amplicons to ensure
specific amplification. A common tag was placed on either
the forward or the reverse primer (depending on the strand
to be sequenced), and a common universal biotinylated
primer was used for all reactions as described previously
(44). PCR was performed as described previously and
cycling conditions included denaturation at 958C for 4 min,
followed by 10 cycles of 948C for 15 s, touchdown from
60–508C (21 degree/cycle) for 15 s and 728C for 20 s, fol-
lowed by a further 30 cycles at 508C annealing temperature.
The second PCR used 2 ml of a 1:10 dilution of the first
PCR as template and the same cycling conditions (13). All
products were confirmed to be single bands by agarose gel
electrophoresis. Methylation values were calculated as an
average of all CpG sites within each assay as determined by
the Pyro Q-CpG Software (Biotage, Uppsala, Sweden).
Blood cell fractionation
Peripheral blood was collected from two healthy female
donors with informed consent. PBMCs were isolated using a
standard Ficoll-paque protocol, and blood cell fractions were
isolated using antibody-coated magnetic microbeads and
MACS MS separation columns (cat: 130-042-201) following
the manufacturers protocol (Miltenyi Biotech, Surrey, UK).
Briefly, 5–10 million PBMCs were incubated with each of
the antibody-coated beads for B-cells (CD19, cat:
130-050-301), T-cells (CD2, cat: 130-091-114) or monocytes
(CD14, cat: 130-050-201). Genomic DNA was extracted
from whole PBMCs and each cell-specific population. Bisul-
phite conversion and pyrosequencing were performed as
described.
Cancer cell lines
DNA was extracted from 62 cell lines from brain (n ¼ 7),
breast (n ¼ 5), colon (n ¼ 5), leukaemia (n ¼ 5), lymphoma
(n ¼ 9), sarcoma (n ¼ 15) and others (n ¼ 16). A full list of
cell line names is included in Supplementary Material,
Table S4. Bisulphite conversion and pyrosequencing were per-
formed as described.
Quantitative RT–PCR
Quantitative RT–PCR was performed for ATM using an
Eppendorf Mastercycler with the following primer pairs:
ATM_F (50-tgctcatacagcaggccata-30) with ATM_R (50-aa
ggctgaatgaaagggtaattc-30) and GAPDH_F (50-ggagtcaacgga
tttggtcgta-30) with GAPDH_R (50-ggcaacaatatccactttaccaga
gt-30). The reaction mix contained 1 SYBR green master
mix (Applied Biosystems, Foster City, CA, USA) and
0.5 mM of each forward and reverse primers in a volume of
30 ml. PCR cycling consisted of 958C for 10 min, then 40
cycles of 958C for 30 s, 608C for 60 s, followed by a meltcurve
analysis. Fold-change in expression was calculated by DDCt
normalized to GAPDH for each sample and normalizing ea
ch of the cell lines to the cell line SKBR3.
Statistical analysis
The majority of statistical analysis in this study was performed
using various R packages as described earlier. The simulated
peak distributions were determined by randomly placing
single peaks across the same tiled region and calculating the
distances to the real repetitive elements and repeating 10 000
times. Kolmogorov–Smirnov test was used to test the signifi-
cance of the difference in distributions (ks.test). We used Wil-
coxon signed rank test for the analysis of methylation
percentages obtained by pyrosequencing (wilcox.test). We
performed further analysis for ATM mvp2a to confirm the sig-
nificance of this difference using 1000 randomized simulations
of the test statistic (W, from the Wilcoxon rank sum test) to
calculate the real P-value of the observed test statistic. We
used either generalized linear model (glm) regression or logis-
tic regression analysis (lm) for further analysis of ATM
MVP2b to assess the associations with phenotypic data. Inter-
quartile analysis was performed by calculating the quartiles
from all of the data (quantile) and counting the number of
cases or controls in each quartile. We then used the x2 test
(chisq.test), odds ratio (oddsratio) and Cochran–Armitage
trend test (independence_test).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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